JP2023553815A5 - - Google Patents

Info

Publication number
JP2023553815A5
JP2023553815A5 JP2023531007A JP2023531007A JP2023553815A5 JP 2023553815 A5 JP2023553815 A5 JP 2023553815A5 JP 2023531007 A JP2023531007 A JP 2023531007A JP 2023531007 A JP2023531007 A JP 2023531007A JP 2023553815 A5 JP2023553815 A5 JP 2023553815A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060650 external-priority patent/WO2022115492A1/en
Publication of JP2023553815A publication Critical patent/JP2023553815A/ja
Publication of JP2023553815A5 publication Critical patent/JP2023553815A5/ja
Pending legal-status Critical Current

Links

JP2023531007A 2020-11-24 2021-11-23 幼若化したt細胞を作製する方法、それを含む組成物、及びその使用方法 Pending JP2023553815A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063117787P 2020-11-24 2020-11-24
US63/117,787 2020-11-24
US202163153881P 2021-02-25 2021-02-25
US63/153,881 2021-02-25
US202163165093P 2021-03-23 2021-03-23
US63/165,093 2021-03-23
PCT/US2021/060650 WO2022115492A1 (en) 2020-11-24 2021-11-23 Methods for making, compositions comprising, and methods of using rejuvenated t cells

Publications (2)

Publication Number Publication Date
JP2023553815A JP2023553815A (ja) 2023-12-26
JP2023553815A5 true JP2023553815A5 (enExample) 2024-12-04

Family

ID=81657994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531007A Pending JP2023553815A (ja) 2020-11-24 2021-11-23 幼若化したt細胞を作製する方法、それを含む組成物、及びその使用方法

Country Status (10)

Country Link
US (2) US12091682B2 (enExample)
EP (1) EP4251742A4 (enExample)
JP (1) JP2023553815A (enExample)
KR (1) KR20230113767A (enExample)
AU (1) AU2021386370A1 (enExample)
CA (1) CA3172507A1 (enExample)
IL (1) IL302744A (enExample)
MX (1) MX2023005491A (enExample)
TW (1) TW202235094A (enExample)
WO (1) WO2022115492A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250248946A1 (en) * 2022-04-15 2025-08-07 Turn Biotechnologies, Inc. Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells
WO2024182539A1 (en) * 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
CN1263473A (zh) 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
AU784589B2 (en) 1999-11-30 2006-05-04 Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DE60233137D1 (de) 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
CA2455951A1 (en) 2001-08-03 2003-02-20 The Board Of Trustees Of The Leland Stanford Junior University Bi-directional synthesis of oligoguanidine transport agents
WO2003049772A2 (en) 2001-12-11 2003-06-19 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US7232842B2 (en) 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
US7151116B2 (en) 2003-01-13 2006-12-19 Board Of Trustees Of The Leland Stanford Junior University Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
CA2643826A1 (en) 2006-02-27 2008-06-12 Paul A. Wender Compositions and methods for transport of molecules with enhanced release properties across biological barriers
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2008089053A2 (en) 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
ES2799897T3 (es) 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
EP3231869A1 (en) 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JPWO2011096482A1 (ja) * 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN103562376B (zh) * 2011-04-08 2017-12-29 国家医疗保健研究所 复壮细胞的方法
ES2654060T3 (es) 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
US20140162366A1 (en) 2012-08-31 2014-06-12 Salk Institute For Biological Studies Generation of vascular progenitor cells
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
CA3038532A1 (en) 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
KR20200131301A (ko) * 2018-03-13 2020-11-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 세포 노화의 역전을 위한 일시적 세포 재프로그래밍
CN108642083B (zh) * 2018-04-28 2022-03-22 安徽中盛溯源生物科技有限公司 一种将t细胞高效诱导成多能干细胞的重编程方法

Similar Documents

Publication Publication Date Title
JP2020127044A5 (enExample)
JP2024023385A5 (enExample)
JP2021169491A5 (enExample)
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2022191211A5 (enExample)
JP2021185136A5 (enExample)
JP2022068302A5 (enExample)
JP2020127428A5 (enExample)
JP2022523200A5 (enExample)
JP2021038271A5 (enExample)
JP2021512414A5 (enExample)
JP2023022224A5 (enExample)
JP2024016014A5 (enExample)
JP2022538797A5 (enExample)
JP2022060295A5 (enExample)
JP2025506484A5 (enExample)
JP2022537813A5 (enExample)
JP2020171301A5 (enExample)
JP2020120660A5 (enExample)
JP2023085551A5 (enExample)
JP2022505647A5 (enExample)
JP2022022379A5 (enExample)
JP2024534771A5 (enExample)
JP2023011759A5 (enExample)